&w=3840&q=100)
Deepak Fertilisers Q1 results: Profit rises 22% to ₹244 cr on higher sales
The company reported a net profit of ₹199.65 crore in the year-ago period, according to a regulatory filing.
Total revenue rose 16.54 per cent to ₹2,658.75 crore during the June quarter of the 2025-26 fiscal year from ₹2,281.33 crore in a year-ago.
Expenses remained higher at ₹2,337.31 crore as against ₹2,023.25 crore in the said period.
DFPCL Chairman and Managing Director said, "The strong start to FY26 underscores the impact of our strategic transformation and disciplined execution. Our continued focus on specialty products, customer engagement, and operational agility is driving tangible results." The company's net debt further reduced even as "we progressed major capital investments," he said, adding, "This reinforces the strength of our business model." DFPCL manufactures both industrial chemicals and fertilisers with a strong presence in Technical Ammonium Nitrate (mining chemicals), industrial chemicals, and crop nutrition (fertilisers).
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
18 minutes ago
- Business Standard
GSK Pharma Q1 results: PAT rises 12% to ₹279 cr, income declines marginally
GlaxoSmithKline Pharmaceuticals on Friday said its consolidated net profit increased 12 per cent year-on-year to ₹279 crore for the June quarter. The drug firm had reported a net profit of ₹249 crore for the June quarter of the last fiscal. Total income declined marginally to ₹849 crore for the first quarter as compared with ₹850 crore in the year-ago period, GlaxoSmithKline Pharmaceuticals said in a regulatory filing. "GSK continues to invest in its innovative portfolio and is on track to launch the much-awaited oncology assets, Jemperli and Zejula. By launching these assets in India, GSK is addressing a critical unmet need amid a rising cancer burden and limited access to advanced therapies," GlaxoSmithKline Pharmaceuticals MD Bhushan Akshikar said. The company continues to invest in its innovative portfolio and is on track to launch the much-awaited oncology assets, Jemperli and Zejula, he added. By launching these assets in India, GSK is addressing a critical unmet need amid a rising cancer burden and limited access to advanced therapies, Akshikar noted. Jemperli (dostarlimab) is an immuno-oncology treatment for second-line dMMR endometrial cancer and Zejula (niraparib), is a PARP inhibitor indicated for advanced and recurrent ovarian cancer. Shares of the company were trading 8.22 per cent down at ₹2,898.40 apiece on BSE. (Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
&w=3840&q=100)
Business Standard
2 hours ago
- Business Standard
Godrej Properties Q1 results: Net profit surges 15% to ₹598 crore
otal income, however, fell to ₹1,620.34 crore in the April-June period of 2025-26 fiscal Press Trust of India New Delhi Godrej Properties Ltd has reported a 15 per cent increase in its consolidated net profit to ₹598.40 crore for the first quarter of this fiscal. Its net profit stood at ₹518.8 crore in the year-ago period. Total income, however, fell to ₹1,620.34 crore in the April-June period of 2025-26 fiscal against ₹1,699.48 crore in the corresponding period of the preceding year, according to a regulatory filing on Friday. During the 2025-26 fiscal, Mumbai-based Godrej Properties posted a net profit of ₹1,389.23 crore on a total income of ₹6,967.05 crore. The company is one of the leading real estate developers in the country. (Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
&w=3840&q=100)
Business Standard
6 hours ago
- Business Standard
NISAR launch among world's most precise, says Isro chief Narayanan
Isro Chairman V Narayanan has said the successful launch of the NISAR satellite was one of the most precise launches in the world, and NASA was excited to see that India could successfully carry it out using the indigenously developed GSLV Mark vehicle. He was speaking to reporters on Thursday night at the international airport here, a day after Isro successfully placed the NISAR (NASAIsro Synthetic Aperture Radar) mission onboard a GSLV-F16 rocket from this spaceport. "They were so excited to understand that Indians could successfully launch using the indigenously developed GSLV marked vehicle--our own vehicle for placing the satellite into orbit. They were excited and extremely happy," he said in response to a query. According to Narayanan, it was one of the most precise launches in the world, with a five-stage rocket operating flawlessly at every stage, injecting the satellite into its precise orbit with a margin of just two to three kilometres. "It is an unimaginable achievement even for them," the Isro chairman said. "It is one of the most precise launches that has ever happened in the entire country today can be proud that a very technologically intensive and highly useful satellite built jointly by India and America is placed in orbit using the Indian launcher," he said. (Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
